Please enter the email address you used to register, then we will send you a link to choose a new password
STOK: 101% | Stoke Therapeutics shares are trading higher after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.
VKTX: 21% | Viking Therapeutics shares are trading higher after the company announced results from its Phase 1 multiple ascending dose clinical trial of an oral tablet formulation of VK2735.
MESO: 49% | Mesoblast shares are trading higher after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.
Posted In: MESO STOK VKTX